Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 3 of about 3   

Articles published

DVAX 17.10 0.00 (0.00%)
price chart
3 Vaccine Companies With Upcoming Catalysts
Dynavax Technologies Corporation (NASDAQ:DVAX), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Related articles »  
Andrew Gengos out, John Walker in as Neuraltus CEO
KAI was bought by Amgen Inc. this year for $412 million, Novacea merged with Transcept Pharmaceuticals Inc. in early 2009, and Renovis merged with Evotec AG in 2008.
FDA Approval of Dynavax's (DVAX) Groundbreaking Hep-B Vacccine Could ...
With a current market value of $800 million and the market for hep-B vaccines at about $1.5 billion, sales of Dynavax's proposed vaccine getting about half the market share by 2018 could double the value of the company. Shares are up about 4 percent ...